



^{99m}Tc-Maraciclalide Phase I Data Published in Nuclear Medicine Communications

London, UK, 14 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ^{99m}Tc-maraciclalide, announces the publication of Phase I data demonstrating the safety, biodistribution and radiation dosimetry of ^{99m}Tc-maraciclalide in the April 2024 edition of Nuclear Medicine Communications.

^{99m}Tc-maraciclalide has been demonstrated to be safe and well tolerated in healthy male and female volunteers. The biodistribution data and radiation dosimetry calculations gave an effective dose similar to other ^{99m}Tc agents used in nuclear imaging and supports the use of ^{99m}Tc-maraciclalide in further clinical studies.

The online publication “Safety, biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide ^{99m}Tc-maraciclalide in healthy volunteers” is available [here](#). Authors on the paper are Dr Tatjana Gibbons from the Nuffield Department of Women's and Reproductive Health, University of Oxford, John Radcliffe Hospital, Oxford; Professor Alan Perkins from the Radiological Sciences, School of Medicine, University of Nottingham, Nottingham and Dr Jon Barnett of Serac Healthcare, London.

^{99m}Tc-maraciclalide is a radio-labelled tracer which binds with high affinity to the cell adhesion protein $\alpha_v\beta_3$ integrin and images angiogenesis (new blood vessel formation), a key feature of inflammatory arthritis and endometriosis. Clinical trials in both these indications are ongoing.

The original study was carried out in 2003 and the data only recently submitted for publication as part of Serac Healthcare’s ongoing development programme.

-ENDS-

Maraciclalide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

For more information, please contact:

Serac Healthcare Ltd

www.serachealthcare.com

David Hail, Chief Executive Officer

+44 (0)208 948 0000
info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010820
francettacarr@seraclifesciences.com

Notes to Editors

About Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and

to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Ltd.